One company to watch right now is Pfizer (PFE). PFE is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock is trading with P/E ratio of 7.71 right now. For comparison ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best large-cap value stocks to buy as the recession hits. Goldman Sachs highlighted that equities ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President Donald Trump’s trade war continues to escalate with new tariffs.

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The company’s shares closed yesterday at $22.12.

Pfizer (PFE) stock was up on Monday despite the pharmaceutical company ending the clinical trial of its once-daily GLP-1 weight loss pill, danuglipron. The company had to cut this trial off early ...

I think that PFE is still poised for growth in the next few years, as the most of the negatives seem to have been already priced in by the market a few months ago. Now given Pfizer's growing ...

Pfizer (NYSE:PFE) shares fell on Wednesday after The Wall Street Journal reported that U.S. officials have started an investigation into whether the New York-based pharma giant deliberately ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other blue chip stocks to invest in at 52-week lows. For the first time since 2023, the S&P 500 was seen ...